Work with individual cells significantly faster than using other technologies 
Clones identified with >50% faster timelines* 
Track monoclonal antibody function and sequence from the initial screen 
Automate and scale workflows far beyond manual, time-intensive analysis 
Integrated pipeline for hit-to-lead identification, optimization, and assay development 
Curia’s single B cell cloning workflow enables high-resolution screening with unprecedented speed.
Screen and identify potentially thousands of hit monoclonal antibodies using up to 80,000 NanoPen® chambers per workflow.
Next generation sequencing for barcoded BCR sequences facilitates quick, high-throughput sequence recovery.
Bioinformatics determine sequence diversity and developability. Once threshold plasma titers are reached, hit sequences are returned in just six to twenty days!
Save time and money with an end-to-end workflow that quickly identifies relevant antibodies and provides a seamless path to developing humanized antibodies – in a six-month timeframe or less.
In addition to deploying the Beacon system to identify and select cells of interest, Curia accelerates “First-to-Human” workflows with everything you need to successfully bring a new drug to the clinic, including:
The PentaMice® platform offers superior immunological diversity.
We work with all major human antibody-producing transgenic mouse platforms and specialized genetically modified strains, as well as specialized knockout mice. Clients simply arrange to have the animals shipped to our AAALAC-accredited vivarium for antibody discovery projects.
To quickly generate gram quantities of a unique antibody for further evaluation, Curia utilizes recombinant production (CHO) and delivers a straight path from development to GMP manufacturing.
Save time and resources by using our fully integrated antibody engineering service to reformat lead antibodies to your desired specifications (e.g. scFv or bi-specific). We can also deliver customized viral constructs and engineered cell lines to support CAR-T development and beyond.
Our use of the PentaMice platform provides maximum immunologic diversity early on, so you start with a complex pool of antibodies that have already undergone endogenous in vivo affinity maturation. Then the Beacon system delivers clonal paired antibody sequences from hits right from the start, focusing your program on the antibodies that matter.
Margaret Ho – General Manager and Site Head, Curia San Carlos-Belmont
At Curia, we see every partnership as an opportunity to make an impact together. You can count on our dedicated team to work closely with you from beginning to end, ensuring you receive the communication, support and expertise you need to see your project successfully through to completion.
Whether you’re a small startup with a big idea or an established provider seeking additional production capacity, we can help you get started.
